Anti-Human CD194 (CCR4) Mogamulizumab [Clone KW-0761] – Fc Muted™ HRP
Anti-Human CD194 (CCR4) Mogamulizumab [Clone KW-0761] – Fc Muted™ HRP
Product No.: LT1007
Product No.LT1007 Clone KW-0761 Target CD194 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names Mogamulizumab, CD194, CCR4 Isotype Human IgG1κ Applications ELISA , FA , FC |
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Muted Immunogen Humanization of mouse anti-CCR4 mAb7. Product Concentration 0.5 mg/ml Formulation This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase) Storage and Handling This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2893879 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Mogamulizumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. ELISA Additional Applications Reported In Literature ? FA Additional Reported Applications For Relevant Conjugates ? Depletion Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Mogamulizumab. Clone KW-0761 recognizes human CD194 (CCR4). This product is for research use only. Background Clone KW-0761 (Mogamulizumab) is a research-grade, humanized monoclonal antibody generated from mouse anti-CCR4 mAb7 that targets human CCR4.1 CC chemokine receptor type 4 (CCR4) is a protein that belongs to the G protein-coupled receptor family and is a receptor for a variety of CC chemokines including MCP-1, MIP-1, RANTES, TARC, and Macrophage-derived chemokine. Chemokines are involved in the development, homeostasis, and function of the immune system and are known to regulate cell trafficking of various types of leukocytes. In a 2018 Phase I clinical trial, Mogamulizumab was found to decrease the number of HTLV-1–infected cells and the levels of inflammatory markers related to HTLV-1–Associated Myelopathy.3 Antigen Distribution CCR4 is primarily expressed by Th2 and regulatory T cells in addition to expression on leukemic cells in cutaneous T-cell lymphoma (CTCL). PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars . Cancer . Immuno-Oncology . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade Mogamulizumab biosimilars can be used as analytical calibration standards or reference controls in pharmacokinetic (PK) bridging enzyme-linked immunosorbent assays (ELISAs) to quantitatively measure drug concentration in serum samples, provided their bioanalytical equivalence to the reference (innovator) product has been established. Essential context and supporting details:
In summary, research-grade Mogamulizumab biosimilars, once bioanalytically matched to the reference product, serve as validated calibrators and controls in PK bridging ELISAs, supporting accurate, reproducible measurement of serum drug concentrations in both biosimilar and innovator-treated samples. Biopharma companies utilize a comprehensive suite of structural and functional analytical assays to confirm that a proposed biosimilar is highly similar to its originator (reference) biologic drug. These include detailed studies of primary, secondary, and tertiary structure, post-translational modifications, and assessment of biological activity. Key Analytical Assays for Biosimilarity
Regulatory EmphasisThese analytical studies are foundational, with regulators requiring a "totality of evidence" approach: structural similarity must be complemented by proof that any observed differences do not affect function, safety, or efficacy. Role of Functional AssaysFunctional assays "answer the vital 'so what?' question for any minor structural differences observed," as they test whether any disparities impact the drug's biological activity. These may involve binding to therapeutic targets, effector functions (e.g., antibody-dependent cell-mediated cytotoxicity or ADCC), and other mechanisms relevant to clinical performance. Leinco Biosimilar Use in Analytical StudiesWhile the provided search results do not explicitly mention "Leinco" or describe its biosimilars' use in similarity studies, Leinco Technologies is widely known as a supplier of research-grade biosimilar antibodies and proteins. In biosimilar development and testing, Leinco biosimilars are often used as:
In formal regulatory submissions, however, the reference product used for comparison must be the licensed/original biologic (e.g., as defined by FDA or EMA). Leinco biosimilars typically serve in supporting, not substitutive, roles—such as positive controls, spike-in recovery experiments, or bridging studies in analytical assay development. Summary of Analytical Approaches
In conclusion, multi-parameter analytical characterization—including structure and function—is essential to demonstrate biosimilarity. Leinco biosimilars support preclinical assay validation and QC, but do not substitute for originator/reference drugs in formal regulatory comparison studies. References & Citations1. Yamamoto, K. et al. (2010) J Clin Oncol. 28(9):1591-8. 2. Mimura, Y. et al. (2018) Protein Cell 9(1):47-62. 3. Yamano, Y. et al. (2018) N Engl J Med 378 (6), 529-538. Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
LT1000 | |
LT1003 | |
LT1002 | |
LT1001 | |
LT1006 | |
LT1005 | |
LT1007 |
